News from aidsmap

Life expectancy now near-normal in people with CD4 counts over 350 a year after starting therapy

A large study of 88,504 people with HIV on antiretroviral therapy (ART), published in The Lancet journal and reported widely in the news, has found substantial improvements in life expectancy in people with HIV who started ART after 2008, even in their first year of therapy. People who started ART between 2008 and 2010 and who had achieved CD4 counts over 350 cells/mm3 by the end of their first year of therapy had life expectancies approaching normal.

Read more >>

Protease inhibitor drug suppresses HIV in semen more slowly than drugs from other classes

Protease inhibitors may not be the best class of drug for people newly diagnosed with HIV to start treatment with, if they wish to quickly reduce their risk of passing HIV on to others, a Spanish study has found.

Read more >>

MDR-TB numbers could keep growing despite improved treatment

Up to one-in-three tuberculosis cases in Russia could be multidrug resistant by 2040, and one-in-eight in India, unless more is done to stop the person-to-person spread of drug-resistant TB and suboptimal treatment, a modelling study published in The Lancet Infectious Diseases predicts.

Read more >>

Switching from efavirenz to lopinavir/ritonavir has no meaningful impact on neurological function, says UK study

Switching from efavirenz does not significantly improve the neurological function of patients taking virologically suppressive antiretroviral therapy, investigators from the UK report in HIV Medicine.

Read more >>

Undocumented migrants more likely to be lost to follow-up and have poor virological outcomes after starting ART, Milan study confirms

Undocumented migrants living with HIV have especially poor rates of retention in care and virological suppression after starting antiretroviral therapy (ART), investigators from Italy report in the online edition of the Journal of Acquired Immune Deficiency Syndromes. The single-centre study compared outcomes according to migration and residency status among people starting HIV therapy in Milan between 2001 and 2013. Undocumented migrants were more likely to be lost to follow-up and both documented and undocumented migrants were less likely to attain virological suppression compared to Italian citizens.

Read more >>

Besifovir and tenofovir exalidex look promising as new hepatitis B drugs

Two investigational nucleotide analogue antivirals were shown to be active against hepatitis B virus (HBV) with minimal potential for kidney and bone toxicity, researchers reported at the International Liver Congress last month in Amsterdam. Besifovir is in phase 3 clinical trials, while tenofovir exalidex is in early development.

Read more >>

Naloxone is a heath intervention that can’t be effectively provided without the knowledge and social connections of people who inject drugs

Programmes to provide naloxone, a drug that reverses the effects of opiate overdose, are successful because they harness the social contexts of drug use and train drug users to be ‘indigenous public health workers’ capable of intervening in an overdose, according to a qualitative study published in the May issue of Social Science & Medicine.

Read more >>

Fear of stigma is prompting young South Africans to seek early HIV treatment

Young South Africans are strongly motivated to seek HIV testing and treatment by a desire to maintain a healthy physical appearance and to appear normal to other people, so as to avoid the stigma attached to HIV infection in their communities and peer groups, a qualitative study in South Africa has found.

Read more >>

Increased screening for syphilis boosts detection of early latent infections among Australian gay men

Increased syphilis testing among gay men increased detection of early latent infections and was accompanied by a fall in the proportion of cases involving secondary syphilis, investigators report in the online edition of Clinical Infectious Diseases.

Read more >>

Editors' picks from other sources

A path toward ending AIDS in the US by 2025

from Eurekalert Medicine & Health

Using prevention surveillance data to model rates of HIV incidence, prevalence and mortality, investigators at Brigham and Women's Hospital and Johns Hopkins Bloomberg School of Public Health set targets, specifically a decrease in new infections to 21,000 by 2020 and to 12,000 by 2025, that would mark a transition toward ending the HIV/AIDS epidemic.

The continuum of HIV care: What does it mean and how is Europe doing?

from Eurekalert Inf Dis

From diagnosis of HIV to successful viral suppression: this new ECDC report summarises key findings concerning the Continuum of HIV Care in Europe based on data reported by countries in Europe and Central Asia. In the 37 countries reporting data, an estimated 1.2 million people are living with HIV, 898,000 of whom (75%) have been diagnosed; 88% of these are estimated to be virally suppressed.

New HRI report warns of HIV and hepatitis C 'powder keg' in the European Union ahead of the 25th Harm Reduction International Conference (HR17)

from HIV / AIDS News From Medical News Today

UK based NGO Harm Reduction International (HRI) warns that if the roll back of funding harm reduction services such as needle and syringe programmes and methadone provision in the European Union remained unchecked, renewed spikes in HIV and hepatitis C (HCV) infections amongst people who use drugs were inevitable.

Kenya launches self-test kits and PrEP

from UNAIDS

The Government of Kenya has reinforced its commitment to end AIDS by 2030 by launching two innovative technologies: self-testing for HIV and PrEP.